145549-76-4

Basic information

• Product Name: T-butyl-3-oxocyclobutanecarboxylate
• Synonyms: T-butyl-3-oxocyclobutanecarboxylate;tert-Butyl 3-oxocyclobutanecarboxylate;3-Oxo-cyclobutanecarboxylic acid tert-butyl ester;tert-butyl 3-oxocyclobutane-1-carboxylate;Cyclobutanecarboxylic acid, 3-oxo-, 1,1-diMethylethyl ester
• CAS NO: 145549-76-4
• Molecular Formula: C₉H₁₄O₃
• Molecular Weight: 170.207
• Mol File: 145549-76-4.mol

Chemical Properties

• Boiling Point: 230.414°C at 760 mmHg
• Flash Point: 93.36°C
• Appearance: /
• Density: 1.101g/cm³
• Vapor Pressure: 0.066mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: T-butyl-3-oxocyclobutanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: T-butyl-3-oxocyclobutanecarboxylate(145549-76-4)
• EPA Substance Registry System: T-butyl-3-oxocyclobutanecarboxylate(145549-76-4)

Safety Data

• Hazardous Substances Data: 145549-76-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
T-butyl-3-oxocyclobutanecarboxylate is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex organic molecules, enhancing the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, T-butyl-3-oxocyclobutanecarboxylate is utilized as a precursor in the production of agrochemicals, aiding in the creation of compounds that can improve crop protection and yield.
It is important to handle T-butyl-3-oxocyclobutanecarboxylate with care due to its flammable nature and potential to cause irritation to the skin, eyes, and respiratory system upon exposure.

InChI:InChI=1/C9H14O3/c1-9(2,3)12-8(11)6-4-7(10)5-6/h6H,4-5H2,1-3H3

Upstream product

• 463-82-1 2,2-dimethylpropane 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75-65-0 tert-butyl alcohol 
• 1663-39-4 tert-Butyl acrylate 

Downstream Products

• 939768-64-6 tert-butyl (1s,3s)-3-hydroxycyclobutane-1-carboxylate 
• 1311158-43-6 trans-tert-butyl (1r,3r)-3-hydroxycyclobutane-1-carboxylate 
• 1355091-44-9 tert butyl 3-{6-[(2,6-dichlorophenyl)methoxy]-2H-spiro[1-benzofuran-3,4'-piperidine]-1'-yl}cyclobutane-1-carboxylate 

Relevant articles and documents

Photochemistry of Axially Chiral (Arylmethylene)cycloalkanes: A Search for Suitable Photoswitchable Liquid Crystalline Materials

A series of chiral (arylmethylene)cycloalkanes was synthesized in racemic and optically active form to examine their suitability for incorporation in a liquid crystal-based optical switch.Irradiation of these compounds with UV light leads to their rapid p

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Copper-Catalyzed Radical C-C Bond Cleavage and [4+1] Annulation Cascade of Cycloketone Oxime Esters with Enaminothiones

Carbon-carbon bond formation is among the most important reactions in organic synthesis. Reconstruction of a carbon-carbon bond through ring-opening C-C bond cleavage of a strained carbocycle usually occurs via a thermodynamically preferable pathway. However, carbon-carbon bond formation through thermodynamically less favorable C-C bond cleavage has seldom been documented. Herein, we disclose an unusual C-C bond cleavage of cycloketone oxime esters for [4+1] annulation. Under anaerobic copper(I) catalysis, cycloketone oxime esters underwent regioselective, thermodynamically less favorable radical C-C bond cleavage followed by annulation with enaminothiones; that is, α-thioxo ketene N,S-acetals efficiently affording 2-cyanoalkyl-aminothiophene derivatives. Cyclobutanone, -pentanone, -hexanone, and -heptanone oxime esters could act as the effective C1 building blocks in the annulation reaction. An iminyl radical mechanism is proposed for the rare C-C bond cleavage/[4+1] annulation cascade.

Structure-based design of tricyclic NF-κB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K)

We report here structure-guided optimization of a novel series of NF-κB inducing kinase (NIK) inhibitors. Starting from a modestly potent, low molecular weight lead, activity was improved by designing a type 11/2 binding mode that accessed a back pocket past the methionine-471 gatekeeper. Divergent binding modes in NIK and PI3K were exploited to dampen PI3K inhibition while maintaining NIK inhibition within these series. Potent compounds were discovered that selectively inhibit the nuclear translocation of NF-κB2 (p52/REL-B) but not canonical NF-κB1 (REL-A/p50).

HETEROCYCLIC COMPOUND

The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease

Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer's disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual in vitro inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for in vivo testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit), and the ability to cross the blood-brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing (Cuadrado-Tejedor, M.; Garcia-Barroso, C.; Sánchez-Arias, J. A.; Rabal, O.; Mederos, S.; Ugarte, A.; Franco, R.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A. Neuropsychopharmacology 2016, in press, doi: 10.1038/npp.2016.163).

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):